


Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. *N Engl J Med* 2006;355:1672-81.

Supplemental Figure 1

Platelet counts over time in responding patients (top) and non-responding patients (bottom) treated with AMG 531 or placebo (weekly treatment for 6 weeks). Placebo patients are indicated by a red line. The shaded area shows the targeted platelet range. Platelet counts associated with rescue medication are excluded. On average, the proportion of weekly platelet counts $>50 \times 10^9/L$ was 50% for $1 \mu g/kg$, 80% for $3 \mu g/kg$, and 17% for placebo. The proportion of weekly platelet counts $>100 \times 10^9/L$ was 23%, 35%, and 0%, respectively.



*Patient in 3 µg/kg responder group had a platelet count of 822x10⁹/L at week 6 not shown on the graph.

Supplemental FIGURE 1

Table Supplement. Summary of Adverse Events with an Incidence <10% in Patients Treated with AMG 531

Adverse Event	Part A 2 administrations, 2 weeks apart		Part B Weekly administration for 6 weeks		Part A + Part B
	AMG 531		AMG 531		AMG 531
	0.2 to 1 µg/kg N = 12 n (%)	3 to 10 µg/kg N = 12 n (%)	1 to 6 µg/kg N = 17 n (%)	Placebo N = 4 n (%)	All Doses N = 41 n (%)
Back pain	0	2 (17)	1 (6)	2 (50)	3 (7)
Diarrhea	0	0	3 (18)	1 (25)	3 (7)
Dyspnea	1 (8)	1 (8)	1 (6)	0	3 (7)
Musculoskeletal stiffness	2 (17)	0	1 (6)	0	3 (7)
Pain in extremity	2 (17)	0	1 (6)	0	3 (7)

Pharyngolaryngeal pain	0	2 (17)	1 (6)	0	3 (7)
Purpura	0	0	3 (18)	0	3 (7)
Purpura (not otherwise specified)	2 (17)	1 (8)	0	0	3 (7)
Stomatitis	0	1 (8)	2 (12)	2 (50)	3 (7)
Upper respiratory tract infection	0	0	3 (18)	1 (25)	3 (7)
Venipuncture site bruise	1 (8)	0	2 (12)	0	3 (7)
Vaginal hemorrhage*	0	1 (11)	1 (8)	1 (33)	2 (7)
Abdominal pain	0	0	2 (12)	1 (25)	2 (5)
Anxiety	0	1 (8)	1 (6)	0	2 (5)
Constipation	0	1 (8)	1 (6)	0	2 (5)
Cough	1 (8)	1 (8)	0	0	2 (5)
Dyspepsia	1 (8)	1 (8)	0	0	2 (5)

Erythema	0	0	2 (12)	0	2 (5)
Flushing	0	0	2 (12)	0	2 (5)
Hematochezia	0	0	2 (12)	0	2 (5)
Herpes simplex	0	0	2 (12)	0	2 (5)
Injection site bruising	1 (8)	1 (8)	0	1 (25)	2 (5)
Insomnia	0	0	2 (12)	0	2 (5)
Joint stiffness	1 (8)	1 (8)	0	0	2 (5)
Mouth ulceration	1 (8)	1 (8)	0	0	2 (5)
Muscle cramp	0	0	2 (12)	0	2 (5)
Pain (not otherwise specific)	2 (17)	0	0	0	2 (5)
Rash erythematous	0	0	2 (12)	0	2 (5)
Sinusitis (not otherwise specified)	0	2 (17)	0	0	2 (5)

Tooth abscess	1 (8)	1 (8)	0	0	2 (5)
Toothache	0	1 (8)	1 (6)	1 (25)	2 (5)
Dysmenorrhea*	0	0	1 (8)	0	1 (3)
Menorrhagia*	0	0	1 (8)	0	1 (3)
Abdominal discomfort	0	1 (8)	0	0	1 (2)
Abdominal pain upper	1 (8)	0	0	1 (25)	1 (2)
Anemia	0	0	1 (6)	0	1 (2)
Aphthous stomatitis	0	1 (8)	0	0	1 (2)
Asthenia	0	1 (8)	0	0	1 (2)
Blood pressure increased	0	0	1 (6)	0	1 (2)
Cerebral hemorrhage	1 (8)	0	0	0	1 (2)

Cognitive disorder	0	0	1 (6)	0	1 (2)
Decreased appetite	0	0	1 (6)	0	1 (2)
Depressed mood	0	0	1 (6)	0	1 (2)
Depression	0	0	1 (6)	0	1 (2)
Diarrhea (not otherwise specified)	1 (8)	0	0	0	1 (2)
Ear hemorrhage	0	1 (8)	0	0	1 (2)
Ejaculation disorder (not otherwise specified)*	1 (25)	0	0	0	1 (8)
Esophageal spasm	0	0	1 (6)	0	1 (2)
Eye hemorrhage (not otherwise specified)	1 (8)	0	0	0	1 (2)
Eye injury (not otherwise specified)	1 (8)	0	0	0	1 (2)
Feces discolored	1 (8)	0	0	0	1 (2)

Fibrosis (not otherwise specified)	0	1 (8)	0	0	1 (2)
Flatulence	0	1 (8)	0	0	1 (2)
Fungal infection	0	0	1 (6)	0	1 (2)
Gastroesophageal reflux disease	1 (8)	0	0	0	1 (2)
Hematoma (not otherwise specified)	1 (8)	0	0	0	1 (2)
Hematuria	0	0	1 (6)	0	1 (2)
Hemoptysis	0	0	1 (6)	0	1 (2)
Hemorrhage	0	0	1 (6)	0	1 (2)
Hyperkeratosis	0	1 (8)	0	0	1 (2)
Hypoesthesia	0	1 (8)	0	0	1 (2)
Joint dislocation	0	0	1 (6)	0	1 (2)
Joint swelling	0	1 (8)	0	0	1 (2)

Laryngitis	0	0	1 (6)	0	1 (2)
Lethargy	0	0	1 (6)	0	1 (2)
Lipodystrophy acquired	0	1 (8)	0	0	1 (2)
Loose stools	0	0	1 (6)	0	1 (2)
Menstruation irregular*	0	1 (11)	0	0	1 (3)
Migraine	0	0	1 (6)	0	1 (2)
Muscle spasms	0	1 (8)	0	0	1 (2)
Myalgia	0	1 (8)	0	0	1 (2)
Nail bed bleeding	0	0	1 (6)	0	1 (2)
Nasopharyngitis	0	1 (8)	0	0	1 (2)
Neck pain	1 (8)	0	0	1 (25)	1 (2)

Oral mucosal petechiae	0	1 (8)	0	0	1 (2)
Osteopenia	0	1 (8)	0	0	1 (2)
Paraesthesia	1 (8)	0	0	0	1 (2)
Premenstrual syndrome*	0	1 (11)	0	0	1 (3)
Pruritus	0	0	1 (6)	0	1 (2)
Pyrexia	0	1 (8)	0	0	1 (2)
Rash	0	0	1 (6)	0	1 (2)
Rash papular	0	0	1 (6)	0	1 (2)
Rash scaly	0	0	1 (6)	0	1 (2)
Rectal hemorrhage	0	0	1 (6)	2 (50)	1 (2)
Retinal hemorrhage	0	1 (8)	0	0	1 (2)

Rigors	1 (8)	0	0	0	1 (2)
Scoliosis	0	1 (8)	0	0	1 (2)
Sinus headache	0	1 (8)	0	0	1 (2)
Sinusitis	0	0	1 (6)	0	1 (2)
Sinusitis acute (not otherwise specified)	1 (8)	0	0	0	1 (2)
Skin laceration	0	1 (8)	0	0	1 (2)
Skin ulcer	0	0	1 (6)	0	1 (2)
Sleep disorder	0	0	1 (6)	0	1 (2)
Tachycardia (not otherwise specified)	0	1 (8)	0	0	1 (2)
Thermal burn	0	0	1 (6)	0	1 (2)
Tongue hemorrhage	0	1 (8)	0	0	1 (2)

Tremor	0	0	1 (6)	0	1 (2)
Upper respiratory tract infection viral (not otherwise specified)	1 (8)	0	0	0	1 (2)
Urinary tract infection	0	0	1 (6)	0	1 (2)
Varicose veins (not otherwise specified)	0	1 (8)	0	0	1 (2)
Vascular insufficiency	0	1 (8)	0	0	1 (2)
Vertigo	1 (8)	0	0	0	1 (2)
Vision blurred	0	1 (8)	0	0	1 (2)
Vomiting	0	0	1 (6)	0	1 (2)
Vomiting (not otherwise specified)	1 (8)	0	0	0	1 (2)
Wound (not otherwise specified)	1 (8)	0	0	0	1 (2)
Asthma	0	0	0	1 (25)	0

Confusional state	0	0	0	1 (25)	0
Deep vein thrombosis	0	0	0	1 (25)	0
Eye hemorrhage	0	0	0	1 (25)	0
Flank pain	0	0	0	1 (25)	0
Hemorrhage intracranial	0	0	0	1 (25)	0
Injection site pain	0	0	0	1 (25)	0
Mouth hemorrhage	0	0	0	1 (25)	0

*Proportions based on number of female (or male) patients